文献速递前列腺癌肾癌与肾肿瘤膀胱癌与上尿路尿路上皮癌

免疫治疗联合放疗治疗泌尿生殖系统恶性肿瘤

Combining Immunotherapy with Radiotherapy for the Treatment of Genitourinary Malignancies.
PubMed 文献 · Eur Urol Oncol · 2018-11-16

本文综述免疫检查点抑制剂联合放疗在泌尿生殖系统恶性肿瘤中的理论基础、现有数据和新进展。临床前及非泌尿系肿瘤的临床数据提示联合治疗有效且可耐受,肺癌随机试验显示成功,但前列腺癌试验未明确改善生存,多项泌尿系肿瘤试验正在进行。放疗与免疫治疗的最佳联合方式仍存诸多实际问题。

要点

  • 临床前及临床数据支持放疗兼具免疫刺激和免疫抑制效应。
  • 非泌尿系肿瘤的联合研究提示有效性和可耐受性,肺癌随机试验显示成功。
  • 前列腺癌联合试验未明确改善生存,多项泌尿系肿瘤试验正在进行。

核心结论

  • 临床前和临床试验显示免疫治疗联合放疗在包括泌尿生殖系肿瘤在内的癌症治疗中可能产生协同效应,但尚需更多工作揭示机制并确定最佳给药方式。

研究设计与样本

  • 本文为综述,检索PubMed/Medline中的原始研究,检索词包括「radiation therapy」「radiotherapy」「abscopal effect」「immunotherapy」「combined」「combination」。

主要发现

  • 临床前和临床数据支持放疗兼具免疫刺激和免疫抑制效应。
  • 主要针对非泌尿系肿瘤的临床前和临床研究提示放疗联合免疫治疗有效且可耐受。
  • 早期随机试验显示放疗联合免疫治疗在肺癌中取得成功。
  • 一项探讨免疫治疗联合放疗用于前列腺癌的试验未明确改善生存。
  • 多项泌尿系肿瘤试验正在进行,以识别免疫治疗与放疗的协同作用。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文指出关于放疗与免疫治疗最佳联合方式仍存多个实践和技术问题。
  • 原文指出尚需更多工作揭示机制并确定该治疗的最佳实施方式。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Immunotherapy drugs, particularly checkpoint inhibitors, have recently been approved by the Food and Drug Administration for various malignancies. Preclinical and early clinical data show that combining these agents with radiotherapy may produce an even more potent antitumor effect in the treatment of cancer. OBJECTIVE: To describe the rationale, available data, and emerging data on the use of combined immunotherapy and radiation therapy in the setting of genitourinary (GU) malignancies. EVIDENCE ACQUISITION: We performed a search of primary studies from PubMed/Medline that included combinations of the search terms "radiation therapy," "radiotherapy," "abscopal effect," "immunotherapy," "combined," and "combination." EVIDENCE SYNTHESIS: Preclinical and clinical data support both immune-stimulating and immune-suppressing effects of radiotherapy. Preclinical and clinical studies investigating the combination of radiotherapy with immunotherapy, primarily in the setting of non-GU malignancies, have suggested efficacy and tolerability. Early randomized trials combining radiotherapy and immunotherapy have demonstrated success in lung cancer. Although a trial investigating combined immunotherapy and radiotherapy use for prostate cancer did not clearly improve survival, trials are ongoing in multiple GU malignancies to identify synergy between immunotherapy and radiotherapy. Several practical and technical questions remain about the optimal combination of radiotherapy and immunotherapy. CONCLUSIONS: Preclinical and clinical trials show that the combination of the immunotherapy and radiation therapy has the potential to provide a synergistic effect in treating cancer, including GU malignancies, although more work is needed to uncover the mechanism and determine the optimal delivery of this treatment. PATIENT SUMMARY: This paper reviews evidence that immunotherapy drugs can be given together with radiation therapy to improve outcomes in cancers of the genitourinary tract. We find promising initial results and raise important questions that need to be answered before this type of treatment can be utilized successfully.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Solanki AA, Bossi A, Efstathiou JA, et al. Combining Immunotherapy with Radiotherapy for the Treatment of Genitourinary Malignancies. Eur Urol Oncol. 2018. PMID: 30929848. doi:10.1016/j.euo.2018.09.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。